Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of 2019. As more biosimilars referencing these brands become available in the United States in 2020, this year will be pivotal for stakeholders active in the U.S. oncology space to understand the dynamics of how these newly launched biosimilars will affect the coverage and uptake of their reference brands, other originator biologics, and other biosimilars. This report series will track biosimilar and brand use in the United States through real-world data and formulary analysis, with insights from prescribers and payers.
- Biosimilars - Emerging Biosimilars - Special Topics: Oncology Biosimilars In The United States - Wave 2
- Special Topics: Oncology Biosimilars in the United States - Wave 2
Author(s): Marta Delgado
Marta Delgado, Ph.D. is a Business Insight Analyst in the Biosimilars Research team, responsible for the analysis of the biosimilars market across four main therapeutic areas – oncology, endocrinology, immunology and nephrology. Marta holds a Ph.D. in Molecular Neuroscience from University College of London (UCL) and a B.Sc. in Biomedicine from University Pompeu Fabra (UPF), Barcelona. Prior to joining the Biosimilars Research team, Marta worked as a Research Analyst at SKIM, specialising in advanced quantitative studies assessing the potential market opportunities to support life sciences companies in their business decision making.